Humaneered anti-factor B antibody
This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.
1. A humaneered anti-factor B antibody or antigen-binding fragment thereof that selectively binds to factor B within the third short consensus repeat (“SCR”) domain and prevents formation of the C3bBb complex, wherein the antibody comprises a V κ -region polypeptide comprising the amino acid sequence of SEQ ID NO: 16 and a V H -region polypeptide comprising the amino acid sequence of SEQ ID NO: 35.
2. The humaneered anti-factor B antibody or antigen-binding fragment thereof of claim 1 , wherein the antigen-binding fragment is selected from the group consisting of Fab′, (Fab′) 2 , Fv, scFv, and diabodies.
3. The humaneered anti-factor B antibody or antigen-binding fragment thereof of claim 2 , wherein the fragment is a Fab′.
4. A composition comprising the humaneered anti-factor B antibody or antigen-binding fragment thereof of claim 1 , and a pharmaceutically acceptable carrier.